News

Batu Biologics plans to utilize the licensed technology to enhance the potency of the antigen-specific immune response induced by the company’s novel ValloVax™ lung cancer vaccine. The company

Upon completion of the merger, the combined company changed its name to Bone Biologics, Corp and anticipates that trading in the Company’s common stock will commence on the

The lawsuit was filed as a result of Actavis submitting an Abbreviated New Drug Application ("ANDA") to the U.S. Food and Drug Administration ("FDA") in which Actavis is

Dr. Vaughan Clift, Ampio’s Chief Regulatory Officer explained "The seven (7) patient ‘open label’ phase of the 47 patient STRUT study was performed to assure that multiple injections

Under the settlement agreement, the company will pay the amount in a series of tranches through August 2015. The litigation is related to how the company has historically

The new agreements were based on the existing strategic partnership, which includes an oncology research program and co-location of AstraZeneca scientists at the Cancer Research UK Cambridge Institute.

Lymphoseek (technetium Tc 99m tilmanocept) is now indicated for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with

The research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the

The acquisition is part of an ongoing collaboration and option agreement signed by the two companies in November 2012. As part of the acquisition, MorphoSys now has lanthipeptide